Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (159)	4/21/1998 12:28:00 AM
From: Street Walker	Read Replies (1) \| Respond to of 640

Zyprexa - a cash cow Two years ago I did two days on-site DD. Very impressive. LLY was trading then at $63 and has since split. I spoke to the head researchers for Zyprexa and they ended up giving me a tour of all the research facilities and manufacturing process and sites. This was Pre-FDA. Analysts there told me that LLY will make more money off Zyprexa than Prozac. Having spoken to many psychologists since its approval 18 months ago, there seems to be growing sentiment of it becoming the gold standard for psychosis. There are fewer side affects and blood chemistries don't have to be drawn like the antequated drugs. Since then, my interest has been in their options prior to earnings. :-) My favorite pharmaceutical company is PFE. Their drug pannel is awesome! "Out Walkin' the Streets"